“A nutraceutical company runs on the wheels of innate energy fortified with the strength of courage and the ability to recognize that everything is possible”.

 

Risperidone is an atypical antipsychotic developed by Janssen-Cilag and was approved by the United States Food and Drug Administration (FDA) in 1993 for the treatment of schizophrenia. On August 22, 2007, Risperdal was approved as the only drug agent available for treatment of schizophrenia in youth ages 13–18; it was also approved that same day for treatment of bipolar disorder in youth and children ages 10–18, joining lithium. Risperidone contains the functional groups of benzisoxazole and piperidine as part of its molecular structure. In 2003 the FDA approved risperidone for the short-term treatment of the mixed and manic states associated with bipolar disorder. In 2006 the FDA approved risperidone for the treatment of irritability in children and adolescents with autism.

 

Please contact marketing@nutraforlife.com to get a copy of the latest Certificate of Analysis

 

Legal Note

Product exploitation, including development, sales and offer for sale are performed where permissible by patent law. This presentation is not and should not constitute an offer for sale in territories where it is not permitted by law. In USA Products that are Currently on Patent are available for R&D Use in Accordance with 35 USC §271 (e) (1). The Buyer is fully responsible for any legal action.